- Home
- NL vs AVIR Comparison
NL vs AVIR Comparison
Compare NL & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NL | AVIR |
|---|---|---|
| Founded | 1891 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.9M | 236.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NL | AVIR |
|---|---|---|
| Price | $5.79 | $3.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 26.8K | ★ 350.0K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $159,004,000.00 | N/A |
| Revenue This Year | $15.75 | N/A |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $29.02 | ★ N/A |
| Revenue Growth | ★ 5.52 | N/A |
| 52 Week Low | $5.04 | $2.46 |
| 52 Week High | $9.27 | $4.02 |
Technical Indicators
Market Signals| Indicator | NL | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 49.57 |
| Support Level | $5.42 | $3.11 |
| Resistance Level | $5.74 | $3.27 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 79.46 | 52.63 |
Price Performance
Historical ComparisonAbout NL NL Industries Inc.
NL Industries Inc is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).